{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:20:21Z","timestamp":1792120821652,"version":"4.4.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.beha.2018.04.001","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T16:50:57Z","timestamp":1523465457000},"page":"135-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["CAR T cell therapy for B-cell lymphomas"],"prefix":"10.1016","volume":"31","author":[{"given":"Julio C.","family":"Chavez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.beha.2018.04.001_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.04.001_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin."},{"issue":"9","key":"10.1016\/j.beha.2018.04.001_bib3","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.beha.2018.04.001_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.beha.2018.04.001_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2015.12.001","article-title":"Chimeric antigen receptor-redirected T cells return to the bench","volume":"28","author":"Geldres","year":"2016","journal-title":"Semin Immunol"},{"key":"10.1016\/j.beha.2018.04.001_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2018.04.001_bib7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J Immunother"},{"issue":"9","key":"10.1016\/j.beha.2018.04.001_bib8","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"therapy: the CD19 paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J Clin Invest"},{"issue":"5\u20136","key":"10.1016\/j.beha.2018.04.001_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2018.04.001_bib10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10428190701742506","article-title":"B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period","volume":"49","author":"Lim","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.beha.2018.04.001_bib11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2018.04.001_bib12","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2018.04.001_bib13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2018.04.001_bib14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ajh.24169","article-title":"Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET\/CT and rituximab era: a Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"issue":"6769","key":"10.1016\/j.beha.2018.04.001_bib15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.beha.2018.04.001_bib16","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"issue":"44","key":"10.1016\/j.beha.2018.04.001_bib17","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1073\/pnas.1514944112","article-title":"Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens","volume":"112","author":"Young","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.beha.2018.04.001_bib18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.beha.2018.04.001_bib19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2018.04.001_bib20","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res."},{"issue":"9","key":"10.1016\/j.beha.2018.04.001_bib21","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.beha.2018.04.001_bib22","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"117","author":"Gutierrez-Garcia","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2018.04.001_bib23","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-13-1482","article-title":"Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies","volume":"19","author":"Coutinho","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"4","key":"10.1016\/j.beha.2018.04.001_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.12045","article-title":"Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome","volume":"159","author":"Barrans","year":"2012","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.beha.2018.04.001_bib25","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2018.04.001_bib26","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic significance of diffuse large B-Cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies","volume":"33","author":"Scott","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2018.04.001_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrm1703","article-title":"Transcriptional regulation and transformation by Myc proteins","volume":"6","author":"Adhikary","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"17","key":"10.1016\/j.beha.2018.04.001_bib28","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2018.04.001_bib29","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2018.04.001_bib30","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2018.04.001_bib31","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.beha.2018.04.001_bib32","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.beha.2018.04.001_bib33","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2018.04.001_bib34","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.18632\/oncotarget.6262","article-title":"Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma","volume":"7","author":"Ye","year":"2016","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.beha.2018.04.001_bib35","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2018.04.001_bib36","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2018.04.001_bib37","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.beha.2018.04.001_bib38","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2012-01-406033","article-title":"MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation","volume":"119","author":"Cuccuini","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2018.04.001_bib39","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/bjh.14100","article-title":"Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704","volume":"174","author":"Puvvada","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2018.04.001_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","article-title":"Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.beha.2018.04.001_bib41","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first Complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2018.04.001_bib42","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2018.04.001_bib43","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.hoc.2016.07.004","article-title":"Management of relapsed diffuse large B-cell lymphoma","volume":"30","author":"Crump","year":"2016","journal-title":"Hematol Oncol Clin North Am."},{"issue":"27","key":"10.1016\/j.beha.2018.04.001_bib44","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2018.04.001_bib45","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.beha.2018.04.001_bib46","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2018.04.001_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2018.04.001_bib48","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study","volume":"52","author":"Van Den Neste","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.beha.2018.04.001_bib49","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.23524","article-title":"Outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era","volume":"88","author":"Nagle","year":"2013","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1016\/j.beha.2018.04.001_bib50","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.04.001_bib51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.beha.2018.04.001_bib52","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.beha.2018.04.001_bib53","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2018.04.001_bib54","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.beha.2018.04.001_bib55","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2018.04.001_bib56","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration Complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"issue":"16","key":"10.1016\/j.beha.2018.04.001_bib57","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum Interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2018.04.001_bib58","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"355","key":"10.1016\/j.beha.2018.04.001_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"23","key":"10.1016\/j.beha.2018.04.001_bib60","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.183.183","article-title":"Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","volume":"126","author":"Schuster","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2018.04.001_bib61","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3026.3026","volume":"128","author":"Schuster","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2018.04.001_bib62","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-Cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2018.04.001_bib63","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"15_suppl","key":"10.1016\/j.beha.2018.04.001_bib64","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7512","article-title":"Clinical and biologic covariates of outcomes in ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL)","volume":"35","author":"Locke","year":"2017","journal-title":"J Clin Oncol"},{"issue":"S2","key":"10.1016\/j.beha.2018.04.001_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2437_6","article-title":"Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R\/R) diffuse large B-CELL lymphoma (DLBCL)\u2014AN interim analysis","volume":"35","author":"Schuster","year":"2017","journal-title":"Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2018.04.001_bib66","article-title":"Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-Cell lymphoma","volume":"130","author":"Schuster","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.04.001_bib67","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1200\/JCO.2017.35.15_suppl.7513","article-title":"CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001)","volume":"15","author":"Abramson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.04.001_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2437_127","article-title":"High CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001)","volume":"35","author":"Abramson","year":"2017","journal-title":"Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2018.04.001_bib69","article-title":"High durable CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort","volume":"130","author":"Abramson","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2018.04.001_bib70","article-title":"Preliminary safety profile of the CD19-directed defined composition CAR T cell product JCAR017 in relapsed\/refractory aggressive B-NHL patients: potential for outpatient administration","volume":"130","author":"Maloney","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2018.04.001_bib71","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2018.04.001_bib72","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1002\/cncr.28350","article-title":"Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study","volume":"119","author":"Martin","year":"2013","journal-title":"Cancer"},{"issue":"9873","key":"10.1016\/j.beha.2018.04.001_bib73","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.beha.2018.04.001_bib74","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2018.04.001_bib75","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.beha.2018.04.001_bib76","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.04.001_bib77","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month Complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.beha.2018.04.001_bib78","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2018.04.001_bib79","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.beha.2018.04.001_bib80","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.beha.2018.04.001_bib81","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.30795","article-title":"Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: a study report from the Spanish Lymphoma Oncology Group","volume":"123","author":"Provencio","year":"2017","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.beha.2018.04.001_bib82","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.beha.2018.04.001_bib83","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2018.04.001_bib84","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2018.04.001_bib85","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","article-title":"Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma","volume":"25","author":"Glas","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2018.04.001_bib86","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"7360","key":"10.1016\/j.beha.2018.04.001_bib87","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"7337","key":"10.1016\/j.beha.2018.04.001_bib88","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.beha.2018.04.001_bib89","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","article-title":"Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma","volume":"129","author":"Krysiak","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2018.04.001_bib90","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.beha.2018.04.001_bib91","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2018.04.001_bib92","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2018.04.001_bib93","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1100.1100","article-title":"Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with poor prognosis, relapsed or refractory CD19+ follicular lymphoma: prolonged remissions relative to antecedent therapy","volume":"128","author":"Chong","year":"2016","journal-title":"Blood"},{"issue":"224","key":"10.1016\/j.beha.2018.04.001_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.beha.2018.04.001_bib95","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2018.04.001_bib96","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"10.1016\/j.beha.2018.04.001_bib97","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.04.001_bib98","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2018.04.001_bib99","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2018.04.001_bib100","article-title":"Pharmacokinetic, pharmacodynamic and blood analytes associated with clinical response and safety in relapsed\/refractory aggressive B-NHL patients treated with JCAR017","volume":"130","author":"Heipel","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.04.001_bib101","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol"},{"issue":"24","key":"10.1016\/j.beha.2018.04.001_bib102","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1182\/blood-2011-10-386482","article-title":"Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer","volume":"119","author":"Yao","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2018.04.001_bib103","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2018.04.001_bib104","article-title":"Predicting clinical response and safety of JCAR017 in B-NHL patients: potential importance of tumor microenvironment biomarkers and CAR T-cell tumor infiltration","volume":"130","author":"Swanson","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2018.04.001_bib105","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.beha.2018.04.001_bib106","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.04.001_bib107","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"issue":"17","key":"10.1016\/j.beha.2018.04.001_bib108","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2018.04.001_bib109","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","article-title":"Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane","volume":"180","author":"James","year":"2008","journal-title":"J Immunol"},{"issue":"22","key":"10.1016\/j.beha.2018.04.001_bib110","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2803.2803","article-title":"Minimal residual disease negative Complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed\/refractory acute lymphoblastic leukemia (all)","volume":"128","author":"Shah","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2018.04.001_bib111","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.beha.2018.04.001_bib112","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 protein expression in human cancer and normal tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"2","key":"10.1016\/j.beha.2018.04.001_bib113","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol Res."},{"issue":"6","key":"10.1016\/j.beha.2018.04.001_bib114","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res."},{"issue":"23","key":"10.1016\/j.beha.2018.04.001_bib115","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4427.4427","article-title":"Preclinical development of bispecific chimeric antigen receptor targeting both CD19 and CD22","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.04.001_bib116","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2018.04.001_bib117","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2018.04.001_bib118","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.beha.2018.04.001_bib119","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.04.001_bib120","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3389\/fimmu.2017.01221","article-title":"PI3Kdelta inhibition enhances the antitumor fitness of adoptively transferred CD8(+) T cells","volume":"8","author":"Bowers","year":"2017","journal-title":"Front Immunol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T22:42:17Z","timestamp":1720219337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618300227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":120,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1521692618300227"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2018.04.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T cell therapy for B-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2018.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}